secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001193125-23-130432
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio appoints Jeremy Graff, Ph.D. as Class I director
-------------------------------------------------------

- Board expanded from six to seven directors; Graff appointed effective May 1, 2023, term expiring at 2025 annual meeting.
- Graff currently serves as Chief Scientific Officer of IMV, Inc.; previously President/CSO of Biothera Pharmaceuticals and Chief Development Officer at HiberCell.
- Graff will serve on Nominating & Corporate Governance Committee and chair the Science and Technology Committee.
- Compensation follows standard non-employee director policy; company entered into standard indemnification agreement with Graff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523130432/0001193125-23-130432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523130432/d467270d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-130432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer